Skip to main content
Clinical Trials/NCT00003429
NCT00003429CompletedNot Applicable

A Pilot Study of 18F-Flourodeoxyglucose Positron Emission Tomography in the Diagnosis of Primary and Recurrent Cervical Cancer

Memorial Sloan Kettering Cancer Center1 site in 1 countryStarted: May 1998Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Locations
1

Study Overview

Brief Summary

RATIONALE: New imaging procedures such as fludeoxyglucose F 18 PET scan may improve the ability to detect cancer or recurrence of cancer.

PURPOSE: Clinical trial to study the effectiveness of fludeoxyglucose F 18 PET scan in diagnosing primary or recurrent cervical cancer in patients who are undergoing surgery.

Detailed Description

OBJECTIVES:

  • Assess the feasibility of using fludeoxyglucose F 18 (FDG) positron emission tomography (PET) imaging in patients with primary or recurrent cervical cancer.
  • Investigate the ability of FDG-PET scan imaging to detect lymph node metastases in these patients.
  • Investigate the ability of FDG-PET imaging to identify locally advanced disease in early stage cervical cancers.
  • Compare FDG-PET to CT scan imaging with respect to distinguishing between postradiation pelvic fibrosis and recurrent cervical cancer.
  • Investigate the ability of FDG-PET to identify recurrent cervical cancer.

OUTLINE: This is a diagnostic study.

Patients with primary cervical cancer receive fludeoxyglucose F 18 (FDG) intravenously followed 45 minutes later with positron emission tomography (PET) imaging over 60 minutes, as well as computed tomography (CT) scan. Both diagnostic imaging techniques are to assess the abdomen and pelvis, and must be done within 2 weeks prior to surgery. Patients eligible for surgery undergo radical hysterectomy and lymphadenectomy and all specimens are evaluated for correlation with the preoperative diagnostic tests findings.

Patients with recurrent cervical cancer obtain FDG-PET scan and CT scan of the thorax, abdomen, and pelvis prior to surgical exploration for pelvic exenteration. All biopsy specimens are evaluated for correlation with diagnostic tests findings.

Study Design

Study Type
Interventional
Primary Purpose
Diagnostic

Eligibility Criteria

Ages
18 Years to 120 Years (Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Investigators

Study Sites (1)

Loading locations...

Similar Trials

PET Scans in Diagnosing Primary or... | Clinical Trial